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Cardiac hypertrophy is the strongest predictor of the development of heart failure, and anti-hypertrophic treatment holds the 
key to improving the clinical syndrome and increasing the survival rates for heart failure. The paraoxonase (PON) gene cluster 
(PC) protects against atherosclerosis and coronary artery diseases. However, the role of PC in the heart is largely unknown. To 
evaluate the roles of PC in cardiac hypertrophy, transgenic mice carrying the intact human PON1, PON2, and PON3 genes and 
their flanking sequences were studied. We demonstrated that the PC transgene (PC-Tg) protected mice from cardiac hypertro-
phy induced by Ang II; these mice had reduced heart weight/body weight ratios, decreased left ventricular wall thicknesses and 
increased fractional shortening compared with wild-type (WT) control. The same protective tendency was also observed with 
an Apoe/ background. Mechanically, PC-Tg normalized the disequilibrium of matrix metalloproteinases (MMPs)/tissue in-
hibitors of MMPs (TIMPs) in hypertrophic hearts, which might contribute to the protective role of PC-Tg in cardiac fibrosis 
and, thus, protect against cardiac remodeling. Taken together, our results identify a novel anti-hypertrophic role for the PON 
gene cluster, suggesting a possible strategy for the treatment of cardiac hypertrophy through elevating the levels of the PON 
gene family. 
cardiac hypertrophy, fibrosis, paraoxonase gene cluster, angiotensin II 
 
Citation:  Pei, J.F., Yan, Y.F., Tang, X., Zhang, Y., Cui, S.S., Zhang, Z.Q., Chen, H.Z., and Liu, D.P. (2016). Human paraoxonase gene cluster overexpression 





Cardiac hypertrophy, characterized by the enlargement of 
individual myocytes to augment cardiac pump function and 
decrease ventricular wall tension, is a compensatory and 
protective mechanism of cardiomyocytes in response to 
various physiologic and pathologic stimuli. However, con-
tinuous hypertrophic stimulation leads to cardiac dysfunc-
tion, during which the ventricle dilates, the myocardial wall 
thins, and myocardial contractility declines; these phenom-
ena eventually promote the development of heart failure 
(Frey et al., 2004). Presently, heart failure is acknowledged 
as one of the leading causes of morbidity and mortality 
worldwide, and cardiac hypertrophy is the strongest predic-
tor of the development of heart failure (Gardin and Lauer, 
2004). Considering that anti-hypertrophic treatment could 
significantly improve the clinical syndrome and increase 
survival rates, the discovery of new endogenous negative 
regulators of cardiac hypertrophy is key to the development 
of successful therapies for hypertrophic heart disease. 
The paraoxonase (PON) gene cluster (PC), which con-
tains three adjacent genes (PON1, PON2, and PON3) 
(Primo-Parmo et al., 1996), detoxifies oxidized low-density 
lipoprotein (oxLDL) and homocysteine (Hcy) thiolactone. 
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Unlike PON2 and PON3, which are expressed ubiquitously 
in mouse (She et al., 2009), PON1 is expressed primarily in 
the liver and redistributes to a variety of tissues and organs, 
including the heart, through circulating high-density lipo-
protein (HDL) (Deakin et al., 2011; Marsillach et al., 2008). 
It has been demonstrated that PC protects against athero-
sclerosis (She et al., 2009), reduces the incidence of cardio-
vascular diseases (CVD), and is related to diabetes, meta-
bolic syndrome, and aging via anti-oxidative stress. How-
ever, to our knowledge, the role of PC in cardiac hypertro-
phy has not been reported, and little is known about the  
reactivity of the PON gene cluster to hypertrophic     
stimulation. 
In the present study using PC-overexpressing transgenic 
(Tg) (PC-Tg) mice, we showed that PC was a negative reg-
ulator in the development of cardiac hypertrophy induced 
by Ang II. We demonstrated that the mRNA levels of PON2 
and PON3, as well as the protein levels of PON1–3, were 
upregulated by Ang II infusion for 4 weeks and that PC-Tg 
repressed cardiac remodeling by modulating the balance of 
matrix metalloproteinases (MMPs)/tissue inhibitors of 
MMPs (TIMPs).  
RESULTS 
Changes in the expression of PON1-3 in cardiac hyper-
trophy induced by Ang II 
To profile the role of PC in Ang II-induced cardiac hyper-
trophy, we first assessed the expression patterns of PON1–3 
in mouse hearts after Ang II treatment for 4 weeks. We 
found that the mRNA levels of both PON2 and PON3 were 
significantly upregulated by Ang II compared with the sa-
line group, whereas PON1’s mRNA was absent in both 
groups of mouse hearts (Figure 1A–C). However, the pro-
tein levels of PON1, as well as that of PON2 and PON3, 
were detected in both the saline and Ang II-treated groups, 
and they were all markedly upregulated in the hearts from 
mice infused with Ang II (Figure 1D and E). The immuno-
fluorescence assay showed that PON1 was located mainly 
on the edge of the myocardium in the control wild-type 
(WT) mice (Figure 1F). However, after Ang II treatment for 
4 weeks, PON1 protein was detectable in the whole myo-
cardium (Figure 1F). Taken together, these results indicate 
that both the mRNA and protein levels of PON2/3 in- 
creased, while PON1 protein redistributed more readily in 
 
 
Figure 1  PON gene cluster expression increases in mouse hearts with hypertrophy. A–C, The mRNA of PON1 is not detectable in the mouse hearts (A), 
whereas the mRNA levels of PON2 (B) and PON3 (C) increase in mouse hearts with hypertrophy induced by angiotensin II (Ang II). The mRNA levels are 
shown relative to Gapdh. D and E, The protein levels of PON1, PON2 and PON3 increase in the mouse hearts with hypertrophy induced by Ang II. F, PON1 
protein is located mainly on the edge of the myocardium in the control WT mice, and after Ang II treatment for 4 weeks, PON1 protein was detectable in the 
whole myocardium. Eight- to twelve-week-old male wild-type C57LB6 mice were subjected to saline or Ang II infusion for 4 weeks. LVOW, left ventricular 
outer wall. LVIW, left ventricular inner wall. LVMW, left ventricular mid wall. n=3–6 in each group. *, P<0.05; **, P<0.01; ***, P<0.001. 
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the Ang II-induced hypertrophic hearts, thus indicating the 
involvement of PC in cardiac hypertrophy. 
No noticeable cardiac abnormalities in the PC-Tg mice 
in the basal state 
To further define the role of PC in cardiac hypertrophy, we 
used transgenic mice carrying the intact human PON1, 
PON2, and PON3 genes and their flanking sequences (Fig-
ure 2A), which were established in our lab (She et al., 
2009). Mouse genotyping was performed by PCR and aga-
rose gel electrophoresis (Figure 2B). The tissue-specific 
expression of the human PON1 (hPON1), hPON2, and 
hPON3 transgenes was confirmed (She et al., 2009), and we 
found that the mRNA of each of hPON1–3 was detected in 
the PC-Tg mouse hearts (Figure 2C–E). We did not observe 
any difference in the heart weight (HW)/body weight (BW) 
ratios (Figure 2F), cardiac morphology (left ventricular in-
ternal diameter at end-diastole, (LVID; d)) (Figure 2G), or 
cardiac function, including fractional shortening (FS) and 
ejection fraction (EF) (Figure 2H and I), between the PC-Tg 
mice and their non-transgenic littermates. In addition, the 
levels of hypertrophic fetal gene atrial natriuretic peptide 
(ANP) between the WT and PC-Tg mice were not signifi-
cantly different (Figure 2J).   
PC-Tg protects mice from Ang II-induced cardiac hy-
pertrophy 
To examine the role of the PON gene cluster in the devel-
opment of cardiac hypertrophy, we subjected the PC-Tg 
mice and their WT controls to Ang II-induced hypertrophy. 
No significant difference was observed in blood pressure, 
heart rate (Table S1 in Supporting Information) and serum 
lipid profile (data not shown) between the two groups after 
Ang II treatment. Firstly, we assessed the expression pat-
terns of human PON (hPON) 1–3 in PC-Tg mouse hearts 
after Ang II treatment for 4 weeks. We noted that only the 
mRNA and protein levels of hPON1 increased significantly 
by Ang II treatment (Figure 3A and D), whereas the expres-
sion levels of hPON2 and hPON3 remained unchanged in 
mouse hearts (Figure 3B–D). Compared with saline-treated 
littermate controls, Ang II infusion for 4 weeks resulted in 
massive cardiac hypertrophy in the WT mice, as evidenced 
by echocardiographic analysis and an increased ratio of HW 
to BW (Figure 3E–H); in contrast, the PC-Tg mice showed 
less significant increases in HW/BW ratios (Figure 3E–H). 
Similarly, the PC-Tg mice were resistant to Ang II-induced 
thickening of the left ventricular wall (LVW) and decreas-
ing of FS, whereas these were robust in the WT controls 
(Figure 3I and J). In addition, Ang II treatment significantly  
 
 
Figure 2  Transgenic (Tg) mice generation. A, A schematic of the Tg construct used to generate the human PC-Tg mouse line. B, Mouse genotyping for 
PC-Tg was performed by PCR and agarose gel electrophoresis. C–E, Confirmation of the expression of hPON1 (C), hPON2 (D), and hPON3 (E) in the 
hearts from the PC-Tg mice. The mRNA levels are shown relative to Gapdh. F–J, The PC-Tg mice do not show any difference in heart weight (HW)/body 
weight (BW) (F), cardiac morphology (left ventricular internal diameter at end-diastole, (LVID; d)) (G), or cardiac function, including fractional shortening 
(FS) (H), ejection fraction (EF) (I) and mRNA levels of atrial natriuretic peptide (ANP) (J) compared to their WT littermates. n=3–9 in each group. n.s., no 
significance. 
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Figure 3  PC-Tg overexpression suppresses Ang II-induced cardiac hypertrophy in WT mice. A–C, The mRNA level of human PON1 (hPON1) is upregu-
lated in the PC-Tg mouse hearts (A), whereas the mRNA levels of hPON2 (B) and hPON3 (C) remain unchanged in PC-Tg mouse hearts with hypertrophy 
induced by angiotensin II (Ang II). The mRNA levels are shown relative to Gapdh. D, Representative immunoblot images of hPON1, hPON2 and hPON3 in 
the saline- or Ang II-induced PC-Tg mouse hearts. E and F, Echocardiographic images showing representative B-mode images (E) and M-mode images (F) 
from WT and PC-Tg mice treated with saline or Ang II for 4 weeks. G and H, Body weight (BW) (G) and HW/BW ratios (H) of WT and PC-Tg mice treated 
with saline or Ang II for 4 weeks. I and J, Echocardiographic assessment of the left ventricular wall (LVW) thickness (I) and the FS (J) in saline- and Ang 
II-treated WT and PC-Tg mice. K, Fetal gene mRNA levels in the hearts of saline- or Ang II-treated WT and PC-Tg mice. WT and PC-Tg mice of 8–12 
weeks old were treated with saline or Ang II for 4 weeks. s, systole; d, diastole; PW, posterior wall; AW, anterior wall. n=5–17 in each group. n.s., no 
significance, *, P<0.05; **, P<0.01; ***, P<0.001. 
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induced the expression of the fetal genes CTGF, ACTA-1 
and ANP in the heart of the WT mice, but no upregulation 
of these genes was detected in the heart of the PC-Tg mice 
(Figure 3K). 
With the knowledge that the hearts of Apoe/ mice ex-
hibit increased ROS and inflammation production (Satoh et 
al., 2011), we next sought to determine whether PC-Tg pro-
tects against the progression of cardiac hypertrophy in the 
Apoe null backgrounds. PC-Tg Apoe/ mice were generated 
by crossing PC-Tg mice with Apoe/ mice (Figure S1 in 
Supporting Information). Consistent with previous reports 
(Wang et al., 2005), we found that Ang II infusion for 4 
weeks significantly increased cardiac hypertrophy in the 
Apoe/ mice, which was significantly alleviated by the 
PC-Tg (Figure S2A–D in Supporting Information). These 
data, taken together, indicate that PC overexpression sup-
presses the development of cardiac hypertrophy. 
Ang II-induced cardiac fibrosis and imbalance of matrix 
metalloproteinases (MMPs)/tissue inhibitors of MMPs 
(TIMPs) is retarded in PC-Tg mouse hearts 
During hypertrophy, the myocardial fiber angles and myo-
cyte orientation, which are highly organized and move in a 
continuous fashion from the endocardium to the epicardium,  
are replaced by a thickened, poorly organized, myocardial 
extracellular matrix (ECM) and by hypertrophied myocytes 
(Spinale, 2007). We then evaluated the cardiomyocyte 
cross-sectional area and cardiac fibrosis in the hypertrophic 
hearts using wheat germ agglutinin (WGA) staining and 
Masson’s trichrome staining, respectively, with WT back-
grounds. The results showed a decrease in cross-sectional 
area of the cardiomyocytes and substantially lower levels of 
fibrosis in the PC-Tg mice than in the WT mice in the Ang 
II group, while there were no differences between these 
factors in the saline group (Figure 4A–C). 
Given that the disequilibrium of MMPs/TIMPs is the 
driving force behind ECM homeostasis and cardiac fibrosis 
during remodeling, we next determined the protein levels of 
gelatinases (MMP2 and MMP9) (Mann and Spinale, 1998). 
We found that Ang II significantly increased the protein 
levels of MMP2/9, as well as TIMP-2, which serves as a 
receptor for proMMP-2 and promotes its activation by 
MT1-MMP, in the WT hearts, but these effects were signif-
icantly suppressed by PC-Tg (Figure 4D and E). In addition, 
TIMP1, which binds to the catalytic domain of active 
MMPs and thereby inhibits MMP activity by preventing the 
MMPs from accessing their substrates (Spinale, 2007), was 
upregulated in the hearts of Ang II-treated PC-Tg mice  
 
 
Figure 4  Ang II-induced cardiac fibrosis and imbalance of matrix metalloproteinases (MMPs)/tissue inhibitors of MMPs (TIMPs) is retarded in PC-Tg 
mouse hearts. A, Histological analysis of the heart sections from the WT and PC-Tg mice following saline or Ang II infusion. The heart cross-sections were 
stained with WGA (top row; scale bars, 200 μm) and Masson’s trichrome staining (bottom row; scale bars, 500 μm). B and C, Quantification of the cardio-
myocyte cross-sectional area (B) and the fibrotic area (C) in saline- and Ang II-treated WT and PC-Tg mice. D and E, Representative western blot (D) and 
quantification (E) of the western blot showing the expression of MMP2, proMMP9, MMP9, TIMP1 and TIMP2 in the hearts from the WT and PC-Tg mice 
following saline or Ang II infusion. n=3–8 in each group. **, P<0.01; ***, P<0.001. 
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compared with those from WT mice (Figure 4D and E).  
DISCUSSION 
In the present study, we found that the mRNA and protein 
levels of PON2/3 were up-regulated, while more of the 
PON1 protein was redistributed in mouse hypertrophic 
hearts induced by Ang II for 4 weeks. Furthermore, we have 
provided the first evidence that PC overexpression allevi-
ates cardiac remodeling and that the mechanisms underlying 
it might be associated with the suppression of cardiac fibro-
sis by influencing the imbalance in the MMP/TIMP ratios 
induced by Ang II. 
The PC contains three genes, PON1, PON2, and PON3, 
all of which share a high sequence identity and a similar 
protein structure within a given mammalian species 
(Mackness et al., 2002). However, their tissue and cellular 
distribution are quite different. In mice, PON1 is expressed 
mainly in the liver, but it can redistribute to a variety of 
tissues and organs including hearts by associating with HDL 
and secreting into the serum upon expression in the liver 
(Deakin et al., 2011; Marsillach et al., 2008). Indeed, we 
found that PON1 mRNA was absent in the heart but that its 
level in the liver was high, as previously reported (She et 
al., 2009). However, PON1 protein was detectable in the 
WT control hearts and increased significantly in the Ang 
II-induced hypertrophic hearts. Interestingly, we noted that 
the location of PON1 migrated from the edge of the myo-
cardium to the internal myocardium after Ang II treatment. 
Our results imply that the upregulation of PON1 protein in 
hypertrophic hearts is independent of its mRNA level. In-
stead, the increase of PON1 protein might be due to the 
transfer from liver to the heart via HDLs induced by Ang II. 
These data suggest that PON1 protein is involved in cardiac 
hypertrophy via its redistribution to the myocardium. Unlike 
PON1, both PON2 and PON3 are expressed more univer-
sally in mice. In spite of the limited research on the tran-
scriptional regulation of the PONs, it was reported that 
PON2 message and activity were upregulated in mouse liv-
ers after these mice were fed a high-fat, high-cholesterol, 
and cholate-containing diet; in contrast, PON3 expression 
was not significantly altered compared with their chow-fed 
counterparts (Ng et al., 2005). We are the first to report that 
both the mRNA and protein levels of PON2 and PON3 in 
the hearts of mice were upregulated significantly by Ang II 
treatment for 4 weeks. Taken together, these data indicate 
that all of the PON gene family members might be involved 
in cardiac remodeling by increasing their levels in the myo-
cardium, though these increases occur in different manners. 
Currently, although there is no general agreement on the 
natural substrates of PONs, they are recognized as lactonase 
enzymes. Despite the differences in substrates, all of the 
PON1/2/3-null mice developed significantly larger athero-
sclerotic lesions than their WT counterparts when fed a 
high-fat, high-cholesterol diet (Devarajan et al., 2011; Ng et 
al., 2006; Shih et al., 1998, 2015). In a previous study, we 
found that the PC transgene suppressed atherosclerosis de-
velopment and promoted atherosclerotic plaque stability in 
an Apoe/ background (She et al., 2009). Here, we first 
showed that PONs, which are protective factors for athero-
sclerosis, are protective against the progression of cardiac 
hypertrophy induced by Ang II in mice. We demonstrated 
that PC-Tg suppressed the Ang II-induced increases in 
HW/BW ratios and the thickening of the LVW, as well as a 
decrease in the FS of the hearts not only from the WT mice, 
but also from the Apoe/ mice. Moreover, the upregulation 
of fetal gene expression induced by Ang II was significantly 
suppressed in the hearts of the PC-Tg mice. These findings 
indicate that the PON gene cluster protects against Ang 
II-induced cardiac hypertrophy in mice, thus extending our 
knowledge of the role of PONs from atherosclerosis to car-
diac hypertrophy, although additional model such as trans-
aortic constriction (TAC)-induced cardiac hypertrophy is 
still needed to confirm the protective role of PC-Tg in heart. 
Accumulating evidence shows that MMPs and their 
physiological inhibitors, TIMPs, play a pivotal role in the 
cardiac remodeling progress (Spinale, 2007). It was recently 
reported that the transcriptional levels of MMP-2 were up-
regulated during the compensatory period and that the ex-
pression of MMP-9 was increased during the de-compen- 
satory period (Givvimani et al., 2010). The loss or inhibition 
of MMP-9 suppresses the LV remodeling and dysfunction 
after acute pressure overload in mice (Heymans et al., 
2005a). Among the four TIMPs identified to date, TIMP-2 
is unique in that it activates pro-MMP-2 to active MMP-2 
and also inhibits the active MMP-2. It was demonstrated 
that the expression of TIMP-1 and TIMP-2 increased sig-
nificantly in chronic pressure-overloaded human hearts 
(Heymans et al., 2005b). When TIMP-1 was knocked out, 
mice suffered spontaneous LV dilatation, thus indicating the 
importance of the control of cardiac MMP activity by 
TIMP-1 (Roten et al., 2000). In the present study, we found 
that PC-Tg significantly suppressed the Ang II-induced car-
diac remodeling, as revealed by the cardiomyocyte cross- 
sectional area and cardiac fibrosis. Consistent with these 
data, the upregulated levels of MMP2/9 and the MMP2 ac-
tivator, TIMP2, by Ang II in the hearts of the WT mice 
were remarkably decreased by PC-Tg, whereas the inhibitor 
of MMP2/9, TIMP1, was upregulated in the hearts from the 
PC-Tg mice by Ang II, resulting in a shift of the MMPs/ 
TIMPs balance to a better status. Taken together, our data 
support the notion that the PON gene cluster might be an 
anti-fibrotic factor by repressing the protein levels of 
MMP2/9 and TIMP2 and upregulating the protein levels of 
TIMP1.  
Interestingly, an association (case-control) study in a 
United Abrab Emirati population did not find any signifi-
cant differences in the genotype distribution of the PON1 
and PON2 between the LV hypertrophy and non-LV hyper-
trophy groups (Obineche et al., 2001), whereas another epi-
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demiology data show that the serum arylesterase activity of 
left ventricular systolic dysfunction patients was higher 
compared with that in subjects with advanced decompen-
sated heart failure, but lower compared with healthy control 
subjects. These epidemiology data support the notion that 
protein levels or the enzymatic activities of PON family 
members might be associated with cardiac hypertrophy 
(Tang et al., 2011). Our present work offers the first evi-
dence to shed some light on the protective role of PONs on 
cardiac hypertrophy in mice. However, further investiga-
tions are needed to elucidate the underlying mechanisms. 
Considering that ROS plays important roles in the initiation 
and progression of cardiac hypertrophy (Sag et al., 2014), 
and that PON gene family members are anti-oxidative en-
zymes (Furlong et al., 2016), it will be important to clarify 
the anti-ROS function of PC-Tg in the development of car-
diac hypertrophy. 
In conclusion, we have demonstrated that the PON gene 
cluster protects against Ang II-induced cardiac hypertrophy 
possibly through the inhibition of cardiac fibrosis by modu-
lating the balance between MMPs and TIMPs. This discov-
ery suggests a possible strategy for the treatment of cardiac 
hypertrophy through elevating the levels of PON1–3. 
MATERIALS AND METHODS 
Animals 
PC-Tg mice (C57BL/6J background) were constructed, and 
PC-Tg Apoe/ mice were generated as described previously 
(She et al., 2009). All of the animal experiments were per-
formed using 8- to 12-week-old male mice. Non-transgenic 
littermates were used as controls. All of the animal proto-
cols were approved by the Animal Care and Use Committee 
at the Institute of Basic Medical Sciences, Chinese Acade-
my of Medical Sciences, and Peking Union Medical Col-
lege (CAMS & PUMC) (Wang et al., 2016). 
Animal models and histological analysis 
Alzet osmotic mini pumps (model 2004; DURECT Corp.) 
containing 1.44 mg kg1 d1 Ang II (Cat. No. A9525, Sig-
ma-Aldrich, USA) or saline were implanted subcutaneously 
into the mice for 28 days. The analysis of cardiac hypertro-
phy, myocyte cross-sectional area, and fibrosis and immu-
nofluorescence measurements were all carried out essen-
tially as routinely done in our laboratory (Luo et al., 2016). 
Echocardiography of mice and blood pressure meas-
urements 
Echocardiography was performed and analyzed in a blinded 
manner using a VisualSonics Vevo770 ultrasound biomi-
croscope (VisualSonics Inc, Canada) with a 15-MHz linear 
array ultrasound transducer. Mice were anesthetized with 
saturated tribromoethanol for the duration of the recordings. 
The left ventricular (LV) was assessed in both the paraster-
nal long-axis and short-axis views at a frame rate of 120 Hz. 
M-mode images were obtained for measuring the left ven-
tricular wall (LVW) thickness, LV end-diastolic diameter 
(LVEDD) and LV end-systolic diameter (LVESD) at the 
papillary muscle level. The LV fractional shortening (FS) 
was calculated as FS(%)=((LVEDDLVESD)/LVEDD)× 
100. The heart rate and systolic blood pressure of the ani-
mals were measured using tail-cuff plethysmography 
(BP-2000 System; Visitech Systems, USA) as described 
previously (Li et al., 2011). 
Quantitative real-time PCR (q-PCR) 
RNA isolation and q-PCR were performed as previously 
described (Luo et al., 2016), and the q-PCR primers used in 
this study are listed in the Table S1 in Supporting Infor-
mation. 
Western blot analysis  
Murine cardiac tissues were lysed with RIPA lysis buffer 
supplied with a mixture of protease inhibitors. The homog-
enates were sonicated and centrifuged at 4°C for 15 min, 
and the supernatants were used for western blotting. The 
western blot was performed as described previously (Zhou 
et al., 2011). The primary antibodies were used for PON1 
(Abcam, ab24261), PON2 (Epitomics, S1585), PON3 
(Abcam, ab42322), MMP2 (Epitomics, 2008-1), MMP9 
(CST, 2270), TIMP1 (Santa, sc-5538), TIMP2 (Abcam, 
ab1828), GAPDH (Abcam, ab8245). 
Statistical analysis 
Data analysis is performed using Graph-Pad Prism Soft-
ware. All data are presented as the mean±SD. The statistical 
analysis for two groups is performed with an unpaired 
two-tailed Student’s t-test. A one-way analysis of variance 
(ANOVA) followed by a Bonferroni post hoc test is applied 
for multiple testing. P values less than 0.05 are considered 
statistically significant. 
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